This site is intended for healthcare professionals

Sanofi provides update on phase III study evaluating rilzabrutinib for the treatment of pemphigus.

Read time: 1 mins
Last updated:10th Sep 2021
Published:10th Sep 2021
The Phase III PEGASUS trial evaluating rilzabrutinib to treat pemphigus, a rare autoimmune skin condition, did not meet its primary or key secondary endpoints.
Condition: Pemphigus Vulgaris
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest